A Phase 2, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Magnesium in Patients With Primary Biliary Cholangitis (EPICS )
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Jul 2017
At a glance
- Drugs Saroglitazar (Primary)
- Indications Cholangitis; Primary biliary cirrhosis
- Focus Therapeutic Use
- Acronyms EPICS
- Sponsors Zydus Cadila
- 27 Jun 2017 Planned initiation date changed from 1 Apr 2017 to 1 Jul 2017.
- 18 Apr 2017 New trial record
- 12 Apr 2017 Status changed from planning to not yet recruiting.